Comment on OMB-2026-0034-0001

Summary: The American Diabetes Association (ADA) opposes the proposed rule, arguing that it shifts federal research funding from a merit-based, peer-reviewed framework to a subjective, politically-driven process. They express concern that the rule will stifle innovation, create uncertainty for researchers, and potentially harm patients in clinical trials by allowing for easier grant termination.